Similar anxiolytic-like effects following intra-amygdala infusions of benzodiazepine receptor agonist and antagonist: Evidence for the release of an endogenous benzodiazepine inverse agonist in mice exposed to elevated plus-maze test

Brain Research

Volumn 1267, Issue , 2009, Pages 65-76

  Barbalho, Cilene Aparecida ^a   Nunes de Souza, Ricardo L ^b   Canto de Souza, Azair ^a  

^a FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Amygdala; Anxiety; DMCM; Flumazenil; Maze na ve and maze experienced mouse; Midazolam

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 ETHYL 6,7 DIMETHOXY BETA CARBOLINE 3 CARBOXYLIC ACID METHYL ESTER; BENZODIAZEPINE RECEPTOR; BENZODIAZEPINE RECEPTOR BLOCKING AGENT; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; FLUMAZENIL; MIDAZOLAM;

AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG INFUSION; EMOTION; HISTOLOGY; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; TRANQUILIZING ACTIVITY;

AMYGDALA; ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; CARBOLINES; CATHETERIZATION; EXPLORATORY BEHAVIOR; FLUMAZENIL; MALE; MAZE LEARNING; MICE; MICROINJECTIONS; MIDAZOLAM; MOTOR ACTIVITY; RECEPTORS, GABA-A;

ANIMALIA; MUS; RODENTIA;

EID: 63649088069     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.02.042     Document Type: Article

References (78)

1. Albrechet-Souza L., Borelli G.K., and Brandão M.L. Activity of the medial prefrontal cortex and amygdala underlies one-trial tolerance of rats in the elevated plus-maze. J. Neurosci. Meth. 169 (2008) 109-118
2. Allen M.S., Hagen T.J., Trudell M.L., Codding P.W., Skolnick P., and Cook J.M. Synthesis of novel 3-substituted beta-carbolines as benzodiazepine receptor ligands: probing the benzodiazepine receptor pharmacophore. J. Med. Chem. 31 (1988) 1854-1861
3. Atack J.R., Hutson P.H., Collinson N., Marshall G., Bentley G., Moyes C., et al. Anxiogenic properties of an inverse agonist selective for alpha 3 subunit-containing GABA(A) receptors. Br. J. Pharmacol. 144 3 (2005) 357-366
4. Barnard E.A., Skolnick P., Olsen R.W., Mohler H., Sieghart W., Biggio G., Braestrup C., Bateson A.N., and Langer S.Z. International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit structure and receptor function. Pharmacol. Rev. 50 2 (1998) 291-313
5. Belzung C., Le Guisquet A.M., and Crestani F. Flumazenil induces benzodiazepine partial agonist-like effects in BALB/c but not C57BL/6 mice. Psychopharmacology 148 (2000) 24-32
6. Benjamin D., Lal H., and Meyerson L.R. The effects of 5-HT (1B) characterizing agents in the mouse elevated plus-maze. Life Sci. 47 (1990) 195-203
7. Bertoglio L.J., and Carobrez A.P. Previous maze experience required to increase open arm avoidance in rats submitted to the elevated plus-maze model of anxiety. Behav. Brain Res. 108 (2000) 197-203
8. Bertoglio L.J., and Carobrez A.P. Anxiolytic effects of ethanol and phenobarbital are abolished in test-experienced rats submitted to the elevated plus maze. Pharmacol. Biochem. Behav. 73 4 (2002) 963-969
9. Bertoglio L.J., and Carobrez A.P. Anxiolytic-like effects of NMDA/glycine-B receptor ligands are abolished during the elevated plus-maze Trial 2 in rats. Psychopharmacology 170 (2003) 335-342
10. Bertoglio L.J., and Carobrez A.P. Scopolamine given pre-Trial one prevents the one-trial tolerence phenomenon in the elevated plus-maze Trial 2. Behav. Pharmacol. 15 1 (2004) 45-54
11. Blanchard R.J., and Blanchard D.C. Attack and defense in rodents as ethoexperimental models for the study of emotion. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 13 suppl. (1989) S3-S14
12. Brandão M.L., Cardoso S.H., Melo L.L., Motta V., and Coimbra N.C. The neural substrate of defensive behavior in the midbrain tectum. Neurosc. Biobehav. Rev 18 (1994) 339-346
13. Brandão M.L., Anseloni V.Z., Pandóssio J.E., De Araújo J.E., and Castilho V.M. Neurochemical mechanisms of the defensive behavior in the dorsal midbrain. Neurosci. Biobehav. Rev. 23 (1999) 863-875
14. Braestrup C., Schmiechen R., Neef G., Nielsen M., and Petersen E.N. Interaction of convulsive ligands with benzodiazepine receptors. Science 216 (1982) 1241-1243
15. Canto-de-Souza A., Nunes-de-Souza R.L., and Rodgers R.J. Anxiolytic-like effect of WAY-100635 microinfusions into the median (but not dorsal) raphe nucleus in mice exposed to the plus-maze: influence of prior test experience. Brain Res. 928 (2002) 50-59
16. Carobrez A.P., and Bertoglio L.J. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci. Biobehav. Rev. 29 (2005) 1193-1205
17. Cole J.C., and Rodgers R.J. Ethological comparison of the effects of diazepam and acute/chronic imipramine behaviors of mice in the elevated plus-maze. Pharmacol. Biochem. Behav. 52 (1995) 473-478
18. Contó B.M., Carvalho J.G.B., and Benedito M.A.C. Behavioral differences between subgroups of rats with high and low threshold to clonic convulsions induced by DMCM, a benzodiazepine inverse agonist. Pharmacol. Biochem. Behav. 82 (2005) 417-426
19. Cruz A.P.M., Frei F., and Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 49 (1994) 171-176
20. Cruz-Morales S.E., Santos N.R., and Brandão M.L. One trial tolerance to midazolam is due to enhancement of fear and reduction of anxiolytic-sensitive behaviors in the elevated plus-maze retest in rats. Pharmacol. Biochem. Behav. 72 (2002) 973-978
21. Da-Cunha C., Wolfman C., Levi de Stein M., Ruschel A.C., Izquierdo I., and Medina J.H. Anxiogenic effects intra-amygdala injection of the flumazenil, a benzodiazepine receptor antagonist. Funct. Neurology 7 (1993) 401-405
22. Dál-Col M.L.C., Pereira L.O., Rosa V.P., Calixto A.V., Carobrez A.P., and Faria M.S. Lack of midazolam-induced anxiolysis in the plus-maze Trial 2 is dependent on the length of trial 1. Pharmacol. Biochem. Behav. 74 2 (2003) 395-400
23. Dalvi A., and Rodgers R.J. GABAergic influences on plus-maze behaviour in mice. Psychopharmacology 128 (1999) 380-397
24. Davis M. The role of the amygdala in fear-potentiated startle: implications for animal models of anxiety. Trends Pharmacol. Sci. 13 (1992) 35-41
25. Dawson G.R., Crawford S.P., Stanhope K.J., Iversen S.D., and Tricklebank M.D. One-trial tolerance to the effects of chlordiazepoxide on the elevated plus-maze may be due to locomotor habituation, not repeated drug exposure. Psychopharmacology 113 (1994) 570-572
26. De-Souza M.M., Schenberg L.C., and Carobrez A.P. NMDA-coupled periaqueductal gray glycine receptors modulate anxioselective drug effects on plus-maze performance. Behav. Brain Res. 90 (1998) 157-165
27. Engin E., and Treit D. The effects of intra-cerebral drug infusions on animals' unconditioned fear reactions: a systematic review. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 32 (2008) 1399-1419
28. Escarabajal M.D., Torresa C., and Flaherty C.F. The phenomenon of one-trial tolerance to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze test is abolished by previous administration of chlordiazepoxide or buspirone. Life Sci. 73 (2003) 1063-1074
29. A receptors in fear-related behavior. Behav. Neurosci. 106 2 (1992) 336-344
30. Fernandes C., and File S.E. The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol. Biochem. Behav. 54 (1996) 31-40
31. File S.E., and Hitchcott P.K. A theory of benzodiazepine dependence that can explain whether flumazenil will enhance or reverse the phenomena. Psychopharmacology 101 4 (1990) 525-532
32. File S.E., Lister R.G., and Nutt D.J. The anxiogenic action of benzodiazepine antagonists. Neuropharmacology 21 10 (1982) 1033-1037
33. File S.E., Lister R.G., and Nutt D.J. Intrinsic actions of benzodiazepine antagonists. Neurosci. Lett. 32 (1982) 165-168
34. File S.E., Mabbutt P.S., and Hitchcott P.K. Characterization of phenomenon of 'one-trial tolerance' to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze. Psychopharmacology 102 (1990) 98-101
35. File S.E., Zangrossi Jr. H., Viana M., and Graeff F.G. Trial 2 in the elevated plus maze: a different form of fear?. Psychopharmacology 111 (1993) 491-494
36. File S.E., Gonzalez L.E., and Gallant R. Role of the basolateral nucleus of the amygdala in the formation of a phobia. Neuropsychopharmacology 19 (1998) 397-405
37. Franklin K.B., and Paxinos G. The mouse brain in stereotaxic coordinates (1997), Academic Press, California, USA
38. Garcia A.M.B., Cardenas F.R., and Morato S. Effect of different illumination levels on rat behavior in the elevated plus-maze. Physiol. Behav. 85 (2005) 265-270
39. Gonzalez L.E., and File S.E. A five-minute experience in the elevated plus-maze alters the state of the benzodiazepine receptor in the dorsal raphe nucleus. J. Neurosci. 17 4 (1997) 1505-1511
40. Graeff F.G., Silveira M.S.L., Nogueira R., Audi E.A., and De Oliveira R.M.W. Role of the amygdala and periaqueductal gray in anxiety and panic. Behav. Brain Res. 58 (1993) 123-131
41. Graeff F.G., Netto C.F., and Zangrossi H. The elevated T-maze as an experimental model of anxiety. Neurosci. Biobehav. Rev. 23 (1998) 237-246
42. Grahn R.E., Kalman B.A., and Watkins L.R. The elevated plus maze is not sensitive to the effect of stressor controllability in rats. Pharmacol. Biochem. Behav. 52 (1994) 565-570
43. Green S., and Vale A.L. Role of amygdaloid nuclei in the anxiolytic effects of benzodiazepines in rats. Behav. Pharmacol. 3 (1992) 261-264
44. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacology Biochemistry Behavioral 54 (1996) 21-30
45. Holmes A., and Rodgers R.J. Responses of Swiss-Webster mice to repeated plus-maze experience: further evidence for a qualitative shift in emotional state?. Pharmacol. Biochem. Behav. 60 (1998) 473-488
46. Holmes A., and Rodgers R.J. Influence of spatial and temporal manipulations on the anxiolytic efficacy of chlordiazepoxide in mice previously exposed to the elevated plus-maze. Neuroscience Biobehavioral Review 23 (1999) 971-980
47. Jardim M.C., and Guimarães F.S. GABAergic and glutamatergic modulation of exploratory behavior in the dorsomedial hypothalamus. Pharmacology Biochemistry and Behavior 69 (2001) 579-584
48. Jardim M.C., and Guimarães F.S. Role of glutamate ionotropic receptors in the dorsomedial hypothalamic nucleus on anxiety and locomotor behavior. Pharmacology Biochemistry and Behavior 79 3 (2004) 541-546
49. Kapczinsk F., Curran H.V., Gray J., and Lader M. Flumazenil has anxiolytic effect in simulated stress. Psychopharmacology 114 (1994) 187-189
50. Kent J.M., Mathew S.J., and Gorman J.M. Molecular targets in the treatment of anxiety. Biology Psychiatry 52 (2002) 1008-1030
51. Lang P.J., Bradley M.M., and Cuthbert B.N. Emotion, motivation and anxiety, brain mechanisms and psychophysiology. Biology Psychiatry 44 (1998) 1248-1263
52. Lee C., and Rodgers R.J. Effects of benzodiazepine receptor antagonist, flumazenil, on antinociceptive and behavioural responses to the elevated plus-maze in mice. Neuropharmacology 30 12A (1991) 1263-1267
53. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92 (1987) 180-185
54. Malizia A.L., and Nutt D.J. The effects of centrally administered anxiolytic compounds in animal models of anxiety. Clinical Neuropharmacology 18 (1995) 215-232
55. Menard J., and Treit D. Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neuroscience Biobehavioral Review 23 (1999) 591-613
56. Mendes-Gomes J., and Nunes-de-Souza R.L. Concurrent nociceptive stimulation impairs the anxiolytic effect of midazolam injected into the periaqueductal gray in mice. Brain Research 1047 (2005) 97-104
57. Motta V., and Brandão M.L. Aversive and antiaversive effects of morphine in the dorsal periaqueductal gray of rats submitted to the elevated plus-maze test. Pharmacol. Biochem. Behav. 44 (1993) 119-125
58. Moy S.S., Knapp D.J., Criswell H.E., and Breese G.R. Flumazenil blockade of anxiety following ethanol withdrawal in rats. Psychopharmacology 131 (1997) 354-360
59. Nunes-de-Souza R.L., Canto-de-Souza A., Da-Costa M., Fornari R.V., Graeff F.G., and Pelá I.R. Anxiety-induced antinociception in mice: effects of systemic and intra-amygdala administration of 8-OH-DPAT and midazolam. Psychopharmacology 150 (2000) 300-310
60. Nunes-de-Souza R.L., Canto-de-Souza A., and Rodgers R.J. Effects of intra-hippocampal infusion of WAY- 1000635 on plus maze behavior in mice. Influence of site injection and prior test experience. Brain Research 927 (2002) 87-96
61. Nutt D.J., Glue P., Lawson C., and Wilson S. Flumazenil provocation of panic attacks: evidence for altered benzodiazepine receptor sensitivity in panic disorder. Archives of General Psychiatry 47 (1990) 917-925
62. Pellow S., Chopin P., File S.E., and Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14 (1985) 149-167
63. Pellow S., and File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in rat. Pharmacol. Biochem. Behavioral. 24 (1986) 525-529
64. Pesold C., and Treit D. The septum and amygdala differentially mediate the anxiolytic effects of benzodiazepines. Brain Res. 638 (1994) 295-301
65. Pesold C., and Treit D. The central and basolateral amygdala differentially mediate the anxiolytic effects of benzodiazepines. Brain Res. 671 (1995) 213-221
66. Pokk P., and Zharkovsky A. The effects of flumazenil, Ro 15-4513 and beta-CCM on the behaviour of control and stressed mice in the plus-maze test. J. Physiol. Pharmacol. 48 (1997) 253-261
67. Reis L.M., and Canto-de-Souza A. Intra-periaqueductal gray matter injections of midazolam fail to alter anxiety in plus-maze experienced mice. Brain Res. 1231 (2008) 93-102
68. Rodgers R.J., and Shepherd J.K. Influence of prior maze experience on behaviour and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice. Psychopharmacology 113 (1993) 237-242
69. Rodgers R.J., and Johnson N.J.T. Factor analysis of spatiotemporal and plus-maze, ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 52 (1995) 297-303
70. Rodgers R.J., Cao B.J., Dalvi A., and Holmes A. Animal models of anxiety: an ethological perspective. Braz. J. Med. Biol. Res. 30 (1997) 289-304
71. Russo A.S., Guimarães F.S., De Aguiar J.C., and Graeff F.G. Role of benzodiazepine receptors located in the dorsal periaqueductal gray of rats in anxiety. Psychopharmacology 401 (1993) 796-800
72. Savic M.M., Obradovic D.I., Ugresvic N.D., and Cook J.M. Bidirectional effects of benzodiazepine binding site ligands in the elevated plus-maze: differential antagonism by flumazenil and β-CCt. Pharmacol. Biochem. Behav. 79 (2004) 279-290
73. Savic M.M., Obradovic D.I., Ugresvic N.D., and Cook J.M. Benzodiazepine binding site inverse agonist and locomotor activity in rats: bimodal and biphasic influence. Pharmacol. Biochem. Behav. 84 (2006) 35-42
74. 3H]Ro 15-4513: a biochemical and autoradiographic study. J. Neurochem. 48 (1987) 46-52
75. Stephens D.N., Meldrum B.S., Weidmann R., Schneider C., and Grutzner M. Does the excitatory amino acid receptor antagonist 2-APH exhibit anxiolytic activity?. Psychopharmacology 90 (1986) 166-169
76. Treit D., Menard J., and Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. Behav. 44 (1993) 463-469
77. Zangrossi Jr. H., and Graeff F.G. Behavioural effects of intra-amygdala injections of GABA and 5-HT acting drugs in the elevated plus-maze. Braz J Med Biol Res. 27 (1994) 2453-2456
78. Zangrossi Jr. H., Viana M.B., and Graeff F.G. Anxiolytic effect of intraamygdala injection of midazolam and 8-hydroxy-2(di-n-propylamino) tetralin in the elevated T-maze. Eur. J. Pharmacol. 369 (1999) 267-270